Johnson & Johnson

JNJ Health Care Market cap $663B as of Oct 29, 2026 16:00 ET S&P 500

Q3 FY26 Jun 29 – Sep 27, 2026 reported Oct 21, 2026

Revenue$25.40B +6% year over year

Gross profit$17.30B 68% margin

Operating profit$7.22B 28% margin

Net profit$0.21B 1% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Sep 27, 2026).
Item	Value	Share of revenue	Year over year
Revenue	25.40	100%	+6%
Innovative medicine	16.38	65%	+5%
MedTech	8.93	35%
Other revenue	0.09	0%
Cost of revenue	−8.10	32%
Gross profit	17.30	68% margin	−1pp
SG&A	−6.29	25%	+0pp
Other	−3.80	15%	+0pp
Operating profit	7.22	28% margin
Interest & other costs	−7.18
Tax benefit	0.18
Net profit	0.21	1% margin	−21pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 28, 2026).
Item	Value	Share of revenue	Year over year
Revenue	25.3	100%	+7%
Innovative medicine	16.4	65%	+8%
Med tech	8.9	35%	+5%
Cost of revenue	−8.1	32%
Gross profit	17.3	68% margin	+0pp
SG&A	−6.4	25%	+1pp
Other	−3.7	15%	+0pp
Operating profit	7.2	28% margin	+0pp
Interest & other costs	−0.4
Tax	−1.2
Net profit	5.5	22% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 29, 2026).
Item	Value	Share of revenue	Year over year
Revenue	24.1	100%	+10%
Innovative medicine	15.4	64%	+11%
Med tech	8.6	36%	+8%
Cost of revenue	−8.1	34%
Gross profit	16.0	66% margin	+0pp
SG&A	−6.0	25%	+2pp
Other	−3.5	15%	+0pp
Operating profit	6.4	27% margin	+0pp
Interest & other costs	−0.4
Tax	−0.8
Net profit	5.2	22% margin	−28pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 28, 2025).
Item	Value	Share of revenue	Year over year
Revenue	24.0	100%	+7%
Innovative medicine	15.6	65%	+7%
Med tech	8.4	35%	+7%
Cost of revenue	−7.3	30%
Gross profit	16.7	70% margin	+1pp
SG&A	−5.9	25%	+0pp
Other	−3.7	15%	+0pp
Operating profit	7.1	30% margin	+0pp
Other income, net	0.4
Tax	−2.3
Net profit	5.2	21% margin	+9pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 29, 2025).
Item	Value	Share of revenue	Year over year
Revenue	23.7	100%	+6%
Innovative medicine	15.2	64%	+5%
Med tech	8.5	36%	+7%
Cost of revenue	−7.6	32%
Gross profit	16.1	68% margin	−2pp
SG&A	−5.9	25%	−1pp
Other	−3.5	15%	+0pp
Operating profit	6.7	28% margin	+0pp
Interest & other costs	−0.2
Tax	−1.0
Net profit	5.5	23% margin	+2pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q3 FY26 Jun 29 – Sep 27, 2026 reported Oct 21, 2026 Operating margin 28% Net profit $0.21B	Jun 29 – Sep 27, 2026	Oct 21, 2026	$25.4B	+6%	28%	$0.21B	1%
Q2 FY26 Mar 30 – Jun 28, 2026 reported Jul 23, 2026 Operating margin 28% Net profit $5.53B	Mar 30 – Jun 28, 2026	Jul 23, 2026	$25.3B	+7%	28%	$5.53B	22%
Q1 FY26 Dec 29, 2025 – Mar 29, 2026 reported Apr 22, 2026 Operating margin 27% Net profit $5.24B	Dec 29, 2025 – Mar 29, 2026	Apr 22, 2026	$24.1B	+10%	27%	$5.24B	22%
Q3 FY25 Jun 30 – Sep 28, 2025 reported Oct 22, 2025 Operating margin 30% Net profit $5.15B	Jun 30 – Sep 28, 2025	Oct 22, 2025	$24.0B	+7%	30%	$5.15B	21%
Q2 FY25 Mar 31 – Jun 29, 2025 reported Jul 24, 2025 Operating margin 28% Net profit $5.54B	Mar 31 – Jun 29, 2025	Jul 24, 2025	$23.7B	+6%	28%	$5.54B	23%